Caplin Point Laboratories · NSE: CAPLIPOINT · BSE: 524742

Q3 FY25 results · Oct–Dec 2024

Caplin Point Laboratories reported revenue from operations of ₹492.96 crore (up 13.2% from Q3 FY24) and net profit of ₹140.07 crore (up 16.9% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY25	Q3 FY24	YoY	Q2 FY25	QoQ
Revenue from operations	492.96	435.50	+13.2%	483.10	+2.0%
Other income	31.36	17.18	+82.5%	20.77	+51.0%
Total income	524.32	452.68	+15.8%	503.87	+4.1%
Profit before share of associates & JVs and tax	177.27	145.38	+21.9%	168.56	+5.2%
Share of profit/(loss) of associates & JVs	(0.01)	0.03		(0.10)
Net profit for the period	140.07	119.83	+16.9%	130.81	+7.1%
Attributable to shareholders of the company	138.96	117.20	+18.6%	130.80	+6.2%
EPS, basic (₹)	18.28	15.44	+18.4%	17.22	+6.2%
Net margin (%)	28.4	27.5		27.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY25	Q3 FY24	YoY	Q2 FY25	QoQ
Revenue from operations	185.23	132.83	+39.4%	207.93	−10.9%
Other income	28.83	17.90	+61.1%	43.01	−33.0%
Total income	214.06	150.73	+42.0%	250.94	−14.7%
Profit before tax	100.17	74.43	+34.6%	134.66	−25.6%
Net profit for the period	74.71	55.45	+34.7%	105.74	−29.3%
EPS, basic (₹)	9.83	7.30	+34.6%	13.92	−29.4%
Net margin (%)	40.3	41.7		50.9

Consolidated

Filed with BSE: 07 Feb 2025, 17:55 IST
Board meeting: 07 Feb 2025
Period: 01 Oct 2024 to 31 Dec 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 07 Feb 2025, 17:55 IST
Board meeting: 07 Feb 2025
Period: 01 Oct 2024 to 31 Dec 2024
Review status: Unaudited
Source: XBRL filing on BSE